1.Effect of Recombinant Human Thrombopoietin on Platelet Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
Yan XIE ; Ling-Zhi YAN ; Tao YOU ; Xiao-Lan SHI ; Shuang YAN ; Ying-Ying ZHAI ; Jing-Jing SHANG ; Zhi YAN ; Hong-Ying YOU ; Qing-Qing WANG ; De-Pei WU ; Cheng-Cheng FU
Journal of Experimental Hematology 2024;32(2):505-511
Objective:To analyze the effect of recombinant human thrombopoietin(rhTPO)on platelet(PLT)reconstitution after autologous peripheral blood stem cell transplantation(APBSCT)in patients with multiple myeloma(MM).Methods:The clinical data of 147 MM patients who were diagnosed in the First Affiliated Hospital of Soochow University and received APBSCT as the first-line therapy were retrospectively analyzed.According to whether rhTPO was used during APBSCT,the patients were divided into rhTPO group(80 cases)and control group(67 cases).The time of PLT engraftment,blood product infusion requirements,the proportion of patients with PLT recovery to ≥ 50 × 109/L and ≥ 100 × 109/L at+14 days and+100 days after transplantation,and adverse reactions including the incidence of bleeding were compared between the two groups.Results:There were no significant differences between the two groups in sex,age,M protein type,PLT count at the initial diagnosis,median duration of induction therapy before APBSCT,and number of CD34+cells reinfused(all P>0.05).The median time of PLT engraftment in the rhTPO group was 10(6-14)days,which was shorter than 11(8-23)days in the control group(P<0.001).The median PLT transfusion requirement in the rhTPO group during APBSCT was 15(0-50)U,which was less than 20(0-80)U in the control group(P=0.001).At+14 days after transplantation,the proportions of patients with PLT 2 50 × 109/L in the rhTPO group and the control group were 66.3%and 52.2%,while the proportions of patients with PLT ≥ 100 × 109/L were 23.8%and 11.9%,respectively,with no significant differences(all P>0.05).At+100 days after transplantation,the proportion of patients with PLT ≥ 50 × 109/L in rhTPO group and control group was 96.3%and 89.6%,respectively(P>0.05),but the proportion of patients with PLT ≥ 100 × 109/L in rhTPO group was higher than that in control group(75.0%vs 55.2%,P=0.012).There was no difference in the overall incidence of bleeding events in different locations during period of low PLT level of patients between the two groups.In rhTPO group,the rhTPO administration was well tolerated,and the incidences of abnormal liver and kidney function and infection were similar to those in the control group.Conclusion:When MM patients undergo first-line APBSCT,subcutaneous injection of rhTPO can shorten the time of platelet engraftment,reduce the transfusion volume of blood products,and be well tolerated,moreover,more patients have achieve a high level of PLT recovery after transplantation,which is very important for ensuring the safety of APBSCT and maintenance therapy.
2.Construction and evaluation of prognostic nomogram of breast cancer based on risk scoring model of endoplasmic reticulum stress related genes
Jia-wei PEI ; Xiao HUANG ; De-yuan FU
Chinese Journal of Current Advances in General Surgery 2024;27(12):932-937
Objective:To explore the potential value of endoplasmic reticulum stress-related genes(ERSRGs)in assessing the prognosis of breast cancer patients,and to construct a risk scoring model and a prognostic nomogram.Methods:ERSRGs were retrieved from the Genecards data-base,and three machine learning algorithms,namely"LASSO","RF",and"Xgboost",were used in the TCGA database to screen for core prognostic genes and establish a corresponding risk scoring model.The model was externally validated using the GSE20685 and GSE86166 datasets.Based on the risk scoring model,nomograms were further constructed to predict the 3-year and 5-year overall survival(OS)rates of breast cancer patients.The expression of the model genes at the pro-tein and single-cell levels was assessed through the Human Protein Atlas(HPA)and a single-cell sequencing dataset(GSE176078).Results:A total of 1301 ERSRGs were screened from the Genecards database.Among them,237 ERSRGs were differentially expressed between breast cancer and normal tissues.Univariate Cox regression analysis revealed that 22 ERSRGs were as-sociated with the prognosis of breast cancer patients.Through the three machine learning algo-rithms of LASSO,RF,and Xgboost,five ERSRGs(MAP2K6,IFNG,VIM,TH,CEMIP)were identi-fied as core genes related to the prognosis of breast cancer,and an ERSRGs-related risk scoring model and prognostic nomogram were constructed.Both internal and external dataset validations showed significant differences among patients in different risk groups.The C-index,ROC curve,and calibration curve all indicated that the nomogram had good predictive performance.Conclu-sion:In this study,the nomogram constructed based on the ERSRGS-related risk score model can accurately predict the prognosis of breast cancer patients,which can provide certain reference for clinical diagnosis,treatment and the development of new tumor therapeutic targets.
3.Construction and evaluation of prognostic nomogram of breast cancer based on risk scoring model of endoplasmic reticulum stress related genes
Jia-wei PEI ; Xiao HUANG ; De-yuan FU
Chinese Journal of Current Advances in General Surgery 2024;27(12):932-937
Objective:To explore the potential value of endoplasmic reticulum stress-related genes(ERSRGs)in assessing the prognosis of breast cancer patients,and to construct a risk scoring model and a prognostic nomogram.Methods:ERSRGs were retrieved from the Genecards data-base,and three machine learning algorithms,namely"LASSO","RF",and"Xgboost",were used in the TCGA database to screen for core prognostic genes and establish a corresponding risk scoring model.The model was externally validated using the GSE20685 and GSE86166 datasets.Based on the risk scoring model,nomograms were further constructed to predict the 3-year and 5-year overall survival(OS)rates of breast cancer patients.The expression of the model genes at the pro-tein and single-cell levels was assessed through the Human Protein Atlas(HPA)and a single-cell sequencing dataset(GSE176078).Results:A total of 1301 ERSRGs were screened from the Genecards database.Among them,237 ERSRGs were differentially expressed between breast cancer and normal tissues.Univariate Cox regression analysis revealed that 22 ERSRGs were as-sociated with the prognosis of breast cancer patients.Through the three machine learning algo-rithms of LASSO,RF,and Xgboost,five ERSRGs(MAP2K6,IFNG,VIM,TH,CEMIP)were identi-fied as core genes related to the prognosis of breast cancer,and an ERSRGs-related risk scoring model and prognostic nomogram were constructed.Both internal and external dataset validations showed significant differences among patients in different risk groups.The C-index,ROC curve,and calibration curve all indicated that the nomogram had good predictive performance.Conclu-sion:In this study,the nomogram constructed based on the ERSRGS-related risk score model can accurately predict the prognosis of breast cancer patients,which can provide certain reference for clinical diagnosis,treatment and the development of new tumor therapeutic targets.
4.Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma.
Qing Qing WANG ; Li YAO ; Ming Qing ZHU ; Ling Zhi YAN ; Song JIN ; Jing Jing SHANG ; Xiao Lan SHI ; Ying Ying ZHAI ; Shuang YAN ; Wei Qin YAO ; Hong Ying YOU ; De Pei WU ; Cheng Cheng FU
Chinese Journal of Hematology 2023;44(4):328-332
5.Efficacy and safefy of Polymyxin B treatment for neutropenic patients suffering from refractory Gram-negative bacterial bloodstream infection.
Meng ZHOU ; Hui Zhu KANG ; Cheng Yuan GU ; Yue Jun LIU ; Ying WANG ; Miao MIAO ; Jian Hong FU ; Xiao Wen TANG ; Hui Ying QIU ; Cheng Cheng FU ; Zheng Ming JIN ; Cai Xia LI ; Su Ning CHEN ; Ai Ning SUN ; De Pei WU ; Yue HAN
Chinese Journal of Hematology 2023;44(6):484-489
Objective: To assess the efficacy and safety of polymyxin B in neutropenic patients with hematologic disorders who had refractory gram-negative bacterial bloodstream infection. Methods: From August 2021 to July 2022, we retrospectively analyzed neutropenic patients with refractory gram-negative bacterial bloodstream infection who were treated with polymyxin B in the Department of Hematology of the First Affiliated Hospital of the Soochow University between August 2021 to July 2022. The cumulative response rate was then computed. Results: The study included 27 neutropenic patients with refractory gram-negative bacterial bloodstream infections. Polymyxin B therapy was effective in 22 of 27 patients. The median time between the onset of fever and the delivery of polymyxin B was 3 days [interquartile range (IQR) : 2-5]. The median duration of polymyxin B treatment was 7 days (IQR: 5-11). Polymyxin B therapy had a median antipyretic time of 37 h (IQR: 32-70). The incidence of acute renal dysfunction was 14.8% (four out of 27 cases), all classified as "injury" according to RIFLE criteria. The incidence of hyperpigmentation was 59.3%. Conclusion: Polymyxin B is a viable treatment option for granulocytopenia patients with refractory gram-negative bacterial bloodstream infections.
Humans
;
Polymyxin B/adverse effects*
;
Retrospective Studies
;
Gram-Negative Bacterial Infections/complications*
;
Fever/drug therapy*
;
Sepsis/drug therapy*
;
Anti-Bacterial Agents/therapeutic use*
;
Bacteremia/complications*
7.Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis.
Jing XIA ; Ye ZHAO ; Feng CHEN ; Miao MIAO ; Hui Ying QIU ; Xiao MA ; Xiao Wen TANG ; Ying WANG ; Xiao Jin WU ; Zheng Zheng FU ; De Pei WU ; Su Ning CHEN
Chinese Journal of Internal Medicine 2023;62(4):410-415
Objective: To investigate the clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with acute leukemia who are positive for the SET-NUP214 fusion gene (SET-NUP214+AL). Methods: This was a retrospective case series study. Clinical data of 18 patients with SET-NUP214+AL who received allo-HSCT in the First Affiliated Hospital of Soochow University and Soochow Hongci Hematology Hospital from December 2014 to October 2021 were retrospectively analyzed to investigate treatment efficacy and prognosis. The Kaplan-Meier method was used for survival analysis. Results: Of the 18 patients, 12 were male and 6 were female, and the median age was 29 years (range, 13-55 years). There were six cases of mixed phenotype acute leukemia (three cases of myeloid/T, two cases of B/T, one case of myeloid/B/T), nine cases of acute lymphoblastic leukemia (ALL) (one case of B-ALL and eight cases of T-ALL), and three cases of acute myeloid leukemia. All patients received induction chemotherapy after diagnosis, and 17 patients achieved complete remission (CR) after chemotherapy. All patients subsequently received allo-HSCT. Pre-transplantation status: 15 patients were in the first CR, 1 patient was in the second CR, 1 was in partial remission, and 1 patient did not reach CR. All patients were successfully implanted with stem cells. The median time of granulocyte and platelet reconstitution was +12 and +13 days, respectively. With a median follow-up of 23 (4-80) months, 15 patients survived, while 3 patients died. The cause of death was recurrence of SET-NUP214+AL after transplantation. After allo-HSCT, 5 patients relapsed. The estimated 3-year overall survival (OS) and relapse-free survival (RFS) rates were 83.3%±15.2% and 55.4%±20.7%, respectively. Among the 15 patients who achieved CR before transplantation, there was no significant difference in OS and RFS between haploidentical HSCT and matched sibling donor HSCT (all P>0.05). Conclusions: Allo-HSCT can improve the prognosis and long-term survival rate of patients with SET-NUP214+AL. Disease recurrence is the most important factor affecting long-term survival.
Male
;
Female
;
Humans
;
Retrospective Studies
;
Hematopoietic Stem Cell Transplantation/methods*
;
Leukemia, Myeloid, Acute/therapy*
;
Survival Analysis
;
Remission Induction
;
Acute Disease
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*
;
Recurrence
;
Nuclear Pore Complex Proteins
8.A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis.
Yong LIU ; Hong Ying YOU ; Ling Zhi YAN ; Song JIN ; Jing Jing SHANG ; Xiao Lan SHI ; Shuang YAN ; Wei Qin YAO ; De Pei WU ; Wei LIU ; Cheng Cheng FU
Chinese Journal of Hematology 2022;43(4):330-335
Objective: To analyze the clinical characteristics, treatment response, and prognosis of newly diagnosed symptomatic multiple myeloma (MM) patients with systemic light chain amyloidosis (AL) . Methods: The clinical data of 160 patients with newly diagnosed MM treated at the First Affiliated Hospital of Soochow University from January 1, 2017 to October 31, 2018, were retrospectively analyzed. According to the histopathological biopsy results of bone marrow, skin, and other tissues, the patients were divided into two groups according to whether amyloidosis was combined or not, namely, the MM+AL group and the MM group. The clinical characteristics and treatment responses of the two groups were compared. Results: Among the 160 patients with newly diagnosed MM, there were 42 cases in the MM+AL group and 118 cases in the MM group. In terms of clinical features, the involved light chain and non-involved light chain (dFLC) in the MM+AL group was significantly higher than that in the MM group (P=0.039) . After induction treatment, the MM+AL group had a higher overall response rate (85.7%vs 79.7%, P<0.05) and higher excellent partial response (76.2%vs 55.1%, P<0.05) . After a median follow-up of 26 (0.25-41) months, there was no significant difference in the progression free survival and overall survival (OS) between the two groups (P>0.05) . The OS of patients in autologous hematopoietic stem cell transplantation group was better than that in non transplantation group (P<0.05) .The prognosis of patients with cardiac involvement in the MM+AL group was significantly worse than that in the MM group and MM+AL group without cardiac involvement (P<0.001) , with a median OS of only 13 months. Conclusion: The differential diagnosis between the MM+AL and MM groups requires histopathology, particularly for patients with significantly increased dFLC. The overall remission rate of patients in MM+AL group after 4 courses of induction chemotherapy was higher than that in MM group. The prognosis of patients with cardiac involvement in MM+AL group was poor.
Amyloidosis/diagnosis*
;
Humans
;
Immunoglobulin Light Chains
;
Immunoglobulin Light-chain Amyloidosis/therapy*
;
Multiple Myeloma/therapy*
;
Prognosis
;
Retrospective Studies
9.The Role of Whole Body DWI in the Evaluation of Bone Disease in Multiple Myeloma.
Yan XIE ; You-You HUI ; Fei-Rong YAO ; Chun-Hong HU ; Ling-Zhi YAN ; De-Pei WU ; Cheng-Cheng FU
Journal of Experimental Hematology 2022;30(2):501-505
OBJECTIVE:
To explore the characteristics of ADC value changes in DWI of newly diagnosed symptomatic MM patients and its correlation with R-ISS stage.
METHODS:
The data of 148 newly diagnosed symptomatic MM patients treated by whole-body DWI scan at The First Affiliated Hospital of Soochow University from June 2016 to June 2019 were selected and retrospectively analyzed and 30 cases of age-matched healthy people were selected as controls. The differences of ADC values between the patients in normal control group, DWI- group and DWI+ group were compared, and the relationship between ADC values and R-ISS stage in MM patients was compared.
RESULTS:
The plasma cell percentage of the patients in DWI+ group was higher than those in DWI- group. ADC values of vertebra, sternum, rib, pectoral girdle, pelvic girdle of the patients in DWI+ group were significantly higher than those in DWI- group and normal control group. The ADC values of each part of the patients in DWI- group were higher than those in normal control group. ADC values of sternum, rib and pectoral girdle in the patients at R-ISS stage III were higher than those at R-ISS stage I and II, while, there was no statistical difference between R-ISS stage I and II groups. And there was no significant difference in ADC values of other bone parts such as vertebra and pelvic girdle in patients at R-ISS stage Ⅰ-Ⅲ.
CONCLUSION
DWI+ in MM patients is related to higher tumor invasion. The ADC values of the DWI+ group are higher than those of the DWI- group; the bone ADC values of the DWI- patients are still higher than the normal ones. And there is a certain relationship between ADC value and R-ISS stage.
Bone Diseases
;
Diffusion Magnetic Resonance Imaging
;
Humans
;
Multiple Myeloma/diagnostic imaging*
;
Retrospective Studies
;
Whole Body Imaging
10.Etiological analysis and epidemiological significance of plague in Qinghai, 1980-2011
Jian-guo YANG ; Juan JIN ; Pei-song YOU ; Hui XIE ; Cun-xiang LI ; Jian HE ; Lin-de MA ; Hao-ming XIONG ; qiang ZHANG ; Fu-zhang TIAN ; Rui-xia DAI
China Tropical Medicine 2022;22(12):1109-
Abstract: Objective To analyze the pathogenic characteristics and epidemiological significance of human plague related strains in Qinghai Province in recent 30 years, so as to provide scientific basis for on-the-spot disposal and prevention and control measures of plague outbreak in Qinghai Province. Methods A total of 35 strains of Yersinia pestis isolated from 29 typical human plague outbreaks in Qinghai Province from 1980 to 2011 were selected and studied by biochemical fermentation experiments. Virulence factors detection of Fraction 1 antigen (Fra1), virulence antigen (VW), pigmentation (Pgm) and Yersinia pestis Ⅰ (PstⅠ), determinants and genotyping of differential regions (DFRs) were used to study the pathogenic characteristics. At the same time, according to the epidemic situation of human and animal plague in Qinghai Province in recent years, the current situation of plague prevention and control and epidemic characteristics were analyzed. Results The biotypes of 35 strains of Yersinia pestis were classical, and the biotypes of 29 strains (82.86%) were of Qinghai-Tibet Plateau type, mainly distributed in southern Qinghai and around lake areas, 2 strains (5.71%) belonged to Qilian Mountains type, mainly distributed in Qilian mountains, and 6 genotypes were identified by DFR. Among them, 16 were type 5, 12 were type 8, 2 were type 10, 1 was type 36, 3 were type 30 and 1 was type 1b, the strains of type 5 and 1b were mainly distributed around the lake and the southern foot of Qilian Mountains, while the strains of type 8, 10, 36 and 30 were mainly distributed in the southern part of Qinghai. Conclusions The pathogen of Yersinia pestis in Qinghai Plateau has complex biochemical types, the epidemic situation among animals is continuous year after year, the situation of prevention and control is serious, the occurrence and prevalence of plague seriously endanger people's health and social development, so it is necessary to do a solid job in the prevention and control of plague to ensure the safety of people's lives.


Result Analysis
Print
Save
E-mail